Enterprise Value
104.9M
Cash
135.9M
Avg Qtr Burn
-5.75M
Short % of Float
3.90%
Insider Ownership
2.27%
Institutional Own.
79.12%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Masofaniten (EPI-7386) (antiandrogen) combo w/ enzalutamide Details Prostate cancer, Cancer | Phase 2 Update | |
EPI-7386 (antiandrogen) Monotherapy Details Castration-resistant prostate cancer | Phase 1 Data readout | |
masofaniten (EPI-7386) + apalutamide and abiraterone acetate Details Prostate cancer, Cancer | Phase 1 Data readout |